Drug-drug interactions in oncology: Why are they important and can they be minimized?

Critical Reviews in Oncology/Hematology

Volumn 55, Issue 2, 2005, Pages 117-142

  Blower, Peter ^a   De Wit, Ronald ^b,e,f,g   Goodin, Susan ^c,h,i,j,k   Aapro, Matti ^d,l,m,n,o  

^a Poole House   (United Kingdom)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d CLINIQUE DE GENOLIER   (Switzerland)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f European Society of Medical Oncology (ESMO)   (France)

^g EORTC Genitourinary Group

^h ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

ⁱ RUTGERS UNIVERSITY   (United States)

^j Pharmaceutical Services   (Canada)

^k American College of Clinical Pharmacy   (United States)

^l Multidisciplinary Oncology Institute   (Switzerland)

^m International Society for Geriatric Oncology (SIOG)   (Switzerland)

ⁿ European Organization for Research and Treatment of Cancer (EORTC)

^o Multinational Association for Supportive Care in Cancer (MASCC)

more..

Author keywords

Drug drug interactions; Oncology

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CISPLATIN; CORTICOSTEROID; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; GASTROINTESTINAL AGENT; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IRINOTECAN; METHOTREXATE; NEUROKININ 1 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE; UNINDEXED DRUG;

BONE MARROW TOXICITY; CANCER; CARDIOTOXICITY; CONSTIPATION; DEALKYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; GENETICS; GLUCURONIDATION; HEART ARRHYTHMIA; HUMAN; HYDROXYLATION; HYPOCALCEMIA; KIDNEY FUNCTION; LIVER FUNCTION; METHYLATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONCOLOGY; PROTEIN FUNCTION; PROTEIN INTERACTION; REDUCTION; REVIEW; TACHYCARDIA; TOXICITY; VOMITING;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BRONCHODILATOR AGENTS; CARDIOVASCULAR AGENTS; COMORBIDITY; DRUG INTERACTIONS; GASTROINTESTINAL AGENTS; HUMANS; NEOPLASMS; PSYCHOTROPIC DRUGS;

EID: 22144434701     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.03.007     Document Type: Review

References (217)

1. E. Ernst, and B.R. Cassileth The prevalence of complimentary/alternative medicine in cancer: a systematic review Cancer 83 1998 777 782
2. U. Werneke, J. Earl, C. Seydel, O. Horn, P. Crichton, and D. Fannon Potential health risks of complementary alternative medicines in cancer patients Br J Cancer 90 2004 408 413
3. D.M. Eisenberg, R.B. Davis, and S.L. Ettner Trends in alternative medicine use in the United States JAMA 280 1998 1569 1575
4. R. Yancik, and LA.G. Ries Aging and cancer in America Hematol Oncol Clin North Am 14 2000 17 23
5. R. Yancik, P.A. Ganz, C.G. Varricchio, and B. Conley Perspectives in comorbidity and cancer in older patients: approaches to expand the knowledge base J Clin Oncol 19 2001 1147 1154
6. R. Yancik Cancer burden in the aged Cancer 80 1997 1273 1283
7. T. Jörgensen, S. Johansson, A. Kennerfalk, M.A. Wallander, and K. Svarsudd Prescription drug use, diagnoses, and healthcare utilization among the elderly Ann Pharmacother 35 2001 1004 1009
8. J.T. Hanlon, G.G. Fillenbaum, C. Ruby, S. Gray, and A. Bohannon Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective Drugs Aging 18 2001 123 131
9. S. Karas Jr. The potential for drug interactions Ann Emerg Med 10 1981 627 630
10. A. Anantharaju, A. Feller, and A. Chedid Aging liver. A review Gerontology 48 2002 343 353
11. W. Mühlberg, and D. Platt Age-dependent changes of the kidneys: pharmacological implications Gerontology 45 1999 243 253
12. Aapro M, de Wit R, Keefe DL, Blower PR. Enhancing prescription safety in oncology: drug interactions with antineoplastic drugs. Monograph Chapter 1. Sponsored by Postgraduate Institute for Medicine, February 2002.
13. Aapro M, de Wit R, Goodin S, Blower PR. Enhancing prescription safety in oncology: drug interactions with common concomitant medications (antiemetics, analgesics, bisphosphonates, hematopoietic growth factors, antibacterials, antifungals, antivirals). Monograph Chapter 2. Sponsored by Postgraduate Institute for Medicine, September 2003.
14. Aapro M, de Wit R, Goodin S, Blower PR. Enhancing prescription safety in oncology: drug interactions with common concomitant medications (bronchodilators, cardiovascular drugs, gastrointestinal drugs, and psychotropic drugs). Monograph Chapter 3. Sponsored by Postgraduate Institute for Medicine, July 2004.
15. R.A. Lehne Drug-drug and drug-food interactions Pharmacology for nursing care 4th ed 2001 W.B. Saunders Co. Philadelphia 59 65 [chapter 7]
16. R.A.F. de Ligt, A.P. Kourounakis, and A.P. IJzerman Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery Br J Pharmacol 130 2000 1 12
17. P.B. Molinoff, and R.D. Aarons Effects of drugs on beta-adrenergic receptors on human lymphocytes J Cardiovasc Pharmacol 5 1983 S63 S67
18. B.J. Morris, M.J. Millan, and A. Herz Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography J Pharmacol Exp Ther 247 1988 729 736
19. G.R. Wilkinson Pharmacokinetics. The dynamics of drug absorption, distribution, and elimination J.G. Hardman LE. Limbird Goodman & Gilman's the pharmacological basis of therapeutics 10th ed 2001 McGraw-Hill New York 3 29
20. R.J. Bertz, and G.R. Granneman Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Clin Pharmacokinet 32 1997 210 258
21. M.P. Davis, and J. Homsi The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine Support Care Cancer 9 2001 442 451
22. U.I. Schwarz Clinical relevance of genetic polymorphisms in the human CYP2C9 gene Eur J Clin Invest 33 Suppl 2 2003 23 30
23. P.D. Hansten, and J.R. Horn The top 100 drug interactions. A guide to patient management. Year 2001 2001 H&H Publications Edmonds, WA, USA
24. M.F. Fromm Importance of P-glycoprotein for drug disposition in humans Eur J Clin Invest 33 Suppl 2 2003 6 9
25. S.V. Ambudkar, C. Kimchi-Sarfaty, Z.E. Sauna, and M.M. Gottesman P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468 7485
26. Martindale The extra pharmacopoeia 31st ed 1996 Royal Pharmaceutical Society of Great Britain London, UK
27. J.S. de Bono, and C.J. Twelves The oral fluorinated pyrimidines Invest New Drugs 19 2001 41 59
28. J.C. Gutheil, and D.M. Finucane Antimetabolites M.C. Perry The chemotherapy source book 3rd ed 2001 Lippincott Williams & Wilkins Philadelphia 208 227
29. J.L. Grem Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer Oncology (Huntingt) 15 Suppl 2001 13 19
30. J.H. Goldie Drug resistance MC. Perry The chemotherapy source book 3rd ed 2001 Lippincott Williams & Wilkins Philadelphia, PA 37 48
31. C.H. Kohne, J. Wils, and M. Lorenz Randomized phase III study of high-dose fluorouracil given as a weekly 24-h infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952 J Clin Oncol 21 2003 3721 3728
32. S.-I. Kanamitsu, K. Ito, and H. Okuda Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil Drug Metab Dispos 28 2000 467 474
33. J.M. Kolesar, C.L. Johnson, B.L. Freeberg, J.D. Berlin, and J.H. Schiller Warfarin-5-FU interaction - a consecutive case series Pharmacotherapy 19 1999 1445 1449
34. Gleevec® (imatinib) Product Information. Novartis, 2001.
35. A.B. Benson III, and R.M. Goldberg Optimal use of the combination of irinotecan and 5-fluorouracil Semin Oncol 30 Suppl 6 2003 68 77
36. R.H.J. Mathijssen, R.J. van Alphen, and J. Verweij Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2001 2182 2194
37. R.H. Mathijssen, J. Verweij, P. de Bruijn, W.J. Loos, and A. Sparreboom Effects of St John's wort on irinotecan metabolism J Natl Cancer Inst 94 2002 1247 1249
38. F.J. Zucchero, M.J. Hogan, and C.D. Sommer Evaluations of drug interactions 2001 First DataBank St. Louis, MO
39. R. Henriksson, and K. Grankvist Interactions between anticancer drugs and other clinically used pharmaceuticals. A review Acta Oncol 28 1989 451 462
40. P.D. Hansten, and J.R. Horn Drug interactions analysis and management 2001 Facts and Comparisons St. Louis, MO
41. Methotrexate Product Information. Lederle, 1999.
42. V. Stearns, M.D. Johnson, and J.M. Rae Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 2003 1758 1764
43. Fareston® (toremifene) Product Information. Roberts, 2001.
44. Nolvadex® (tamoxifen) Product Information. AstraZeneca, 2001.
45. M. Dowsett, J. Cuzick, A. Howell, I. Jackson ATAC Trialists' Group Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial Br J Cancer 85 2001 317 324
46. M. Baum, A.U. Budzar, and J. Cuzick Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
47. M. Dowsett Drug and hormone interactions of aromatase inhibitors Endocr Relat Cancer 6 1999 181 185
48. A. Montes, T.J. Powles, and M.E.R. O'Brien A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome Eur J Cancer 29A 1993 1854 1857
49. M.E.R. O'Brien, S. Casey, J. Treleaven, and T.J. Powles Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen Eur J Cancer 30A 1994 894 895
50. Taxol® (paclitaxel) Product Information. Bristol-Myers Squibb, 2001.
51. Taxotere® (docetaxel) prescribing information. Aventis Pharmaceuticals, 2003. http://www.aventis-us.com/PIs/taxotere_TXT.html# [accessed June 21, 2004].
52. M. Venturini, G. Lunardi, and L. Del Mastro Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity J Clin Oncol 18 2000 2116 2125
53. G. Grasselli, L. Vigano, and G. Capri Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer J Clin Oncol 19 2001 2222 2231
54. L. van Zuylen, J. Verweij, and A. Sparreboom Role of formulation vehicles in taxane pharmacology Invest New Drugs 19 2001 125 141
55. H. Gelderblom, W.J. Loos, and J. Verweij Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies Eur J Cancer 38 2002 205 213
56. Adriamycin® (doxorubicin) Product Information. Pharmacia & Upjohn, 2001.
57. Ellence® (epirubicin) Product Information. Pharmacia & Upjohn, 2001.
58. G. Minotti, A. Saponiero, and S. Licata Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in the human myocardium Clin Cancer Res 7 2001 1511 1515
59. L. Gianni, P. Dombernowsky, and G. Sledge Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer Ann Oncol 12 2001 1067 1073
60. M. Esposito, M. Venturini, and M.O. Vannozzi Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients J Clin Oncol 17 1999 1132 1140
61. J.-M. Nabholtz, and A. Riva Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 6 Suppl 3 2001 5 12
62. A.F. Baker, and R.T. Dorr Drug interactions with the taxanes: clinical implications Cancer Treat Rev 27 2001 221 233
63. V. Valero, E. Perez, and V. Dieras Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects Semin Oncol 28 4 Suppl 12 2001 15 23
64. R. Advani, G.A. Fisher, and B.L. Lum A phase I trial of doxorubicin, paclitaxel and valspodar (PSC 833), a modulator of multidrug resistance Clin Cancer Res 7 2001 1221 1229
65. F.K. Engels, A.J. Ten Tije, and S.D. Baker Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel Clin Pharmacol Ther 75 2004 448 454
66. P.H.E. Hilkens, L.C. Pronk, and J. Verweij Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin Br J Cancer 75 1997 417 422
67. R.R. Love, H. Leventhal, D.V. Eaterling, and D.R. Nerenz Side effects and emotional distress during cancer therapy Cancer 63 1989 604 612
68. C.M. Lindley, J.D. Hirsch, C.V. O'Neill, M.C. Transau, C.S. Gilbert, and J.T. Osterhaus Quality of life consequences of chemotherapy-induced emesis Qual Life Res 1 1992 331 340
69. R.J. Gralla, D. Osoba, and M.G. Kris Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. An ASCO special article J Clin Oncol 17 1999 2971 2994
70. MASCC Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference Ann Oncol 9 1998 811 819
71. J.M. Koeller, M.S. Aapro, and R.J. Gralla Antiemetic guidelines: creating a more practical treatment approach Support Care Cancer 10 2002 519 522
72. P.R. Blower Granisetron: relating pharmacology to clinical efficacy Support Care Cancer 11 2003 93 100
73. Kytril® (granisetron) Product Information. Roche, 2001.
74. Zofran® (ondansetron) Product Information. GlaxoSmithKline, 2001.
75. Navoban® (tropisetron) Product Information. Novartis (Australia), 1997.
76. Aloxi® (palonosetron HCl) prescribing information. MGI Pharma Inc., MN, USA, 2003.
77. Anzemet® (dolasetron) Product Information. Aventis Pharmaceuticals, Inc., MO, USA, 2003.
78. J.C. Bloomer, S.J. Baldwin, and G.J. Smith Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron Br J Clin Pharmacol 38 1994 557 566
79. P.R. Blower 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications Cancer J 8 2002 405 414
80. K.M. de Bruijn Tropisetron. A review of the clinical experience Drugs 43 Suppl 3 1992 11 22
81. Hayes EM. The cytochrome P-450 enzyme system. http://www.edhayes.com/ startp450.html [accessed June 21, 2004].
82. L. Pichard, I. Fabre, and M. Daujat Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes Mol Pharmacol 41 1992 1047 1055
83. Flockhart DA. Cytochrome P450 drug interaction table. http://medicine.iupui.edu/flockhart/ [accessed June 21, 2004].
84. A.M. Bergman, H.M. Pinedo, and G.J. Peters Steroids affect collateral sensitivity to gemcitabine of multidrug resistant human lung cancer cells Eur J Pharmacol 416 2001 19 24
85. Ostac® (clodronate) Product Information. Hoffman-La Roche (Canada), 1998.
86. Verive M, Jaimovich D. Hypokalemia. Available at eMedicine: http://www.emedicine.com/ped/topic1121.htm. Last updated March 12, 2003 [accessed June 21, 2004].
87. V.F. Naggar, S.A. Khalil, and M.W. Gouda Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans J Pharm Sci 67 1978 1029 1030
88. Prednisone Product Information. Mosby's Drug Consult. Available by subscription at: http://www.mosbysdrugconsult.com [accessed April 30, 2003].
89. Camptosar® Product Information. Pharmacia & Upjohn, 2002.
90. U.S. Food and Drug Administration. FDA approves new drug to combat nausea and vomiting for cancer patients getting chemotherapy. FDA News, March 26, 2003. Available online at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00886.html [accessed June 21, 2004].
91. Emend® (aprepitant) Product Information. Merck, 2003.
92. Aprepitant FDA Advisory Committee Background Package. BG1037.doc Version 3.0 approved, January 31, 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3928B1_01_Merck%20Backgrounder.pdf [accessed June 21, 2004].
93. R.A. Blum, A. Majumdar, and J. McCrea Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects Clin Ther 25 2003 1407 1419
94. Ticlid® (ticlopidine) Product Information. Roche, 2001.
95. Activase® (alteplase) Product Information. Genentech, 2002.
96. Anon. Coxibs + oral anticoagulants: risk of interaction. Prescrire Int 2002;11:85-6.
97. Vioxx® (rofecoxib) Product Information. Merck, 2002.
98. Celebrex® (celecoxib) Product Information. Pfizer, 2002.
99. Bextra® (valdecoxib) Product Information. Pfizer, 2002.
100. U. Werner, D. Werner, T. Rau, M.F. Fromm, B. Hinz, and K. Brune Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans Clin Pharmacol Ther 74 2003 130 137
101. A.R. Manara, M.P. Shelly, K. Quinn, and G.R. Park The effect of metoclopramide on the absorption of oral controlled release morphine Br J Clin Pharmacol 25 1988 518 521
102. G. Mikus, B. Trausch, and C. Rodewald Effect of codeine gastrointestinal motility in relation to CYP2D6 phenotype Clin Pharmacol Ther 61 1997 459 466
103. L. Poulsen, K. Brosen, and L. Arendt-Nielsen Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects Eur J Clin Pharmacol 51 1996 289 295
104. K. Eckhardt, S. Li, and S. Ammon Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation Pain 76 1998 27 33
105. H.L. Kaplan, U.E. Busto, and G.J. Baylong Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability J Pharmacol Exp Ther 281 1997 103 108
106. K.S. Latta, B. Ginsberg, and R.L. Barkin Meperidine: a critical review Am J Ther 9 2002 53 68
107. R.F. Clark, E.M. Wei, and P.O. Anderson Meperidine: therapeutic use and toxicity J Emerg Med 13 1995 797 802
108. Actiq® (fentanyl) Product Information. Cephalon, 2002.
109. Fuzarolidone Product Information. Mosby's Drug Consult, 2003.
110. Zyvox® (linezolid) Product Information. Pharmacia & Upjohn, 2001.
111. Matulane® (procarbazine) Product Information. Sigma-Tau, 2002.
112. Eldepryl® (selegiline) Product Information. Somerset, 1998.
113. P.K. Nijhawan, G. Katz, and S. Winter Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission Crit Care Med 24 1996 1086 1089
114. S. Kesavan, and G.M. Sobala Serotonin syndrome with fluoxetine plus tramadol J R Soc Med 92 1999 474 475
115. H. Sternbach The serotonin syndrome Am J Psychiatry 148 1991 705 713
116. B.J. Mason, and K.H. Blackburn Possible serotonin syndrome associated with tramadol and sertraline coadministration Ann Pharmacother 31 1997 175 177
117. M.H. Schwenk, A.Q. Jumani, and C.R. Rosenberg Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis Pharmacotherapy 18 1998 627 630
118. M. Matsumura, H. Nomura, I. Koni, and H. Mabuchi Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group Nephron 77 1997 164 168
119. Neupogen® (filgrastim) Product Information. Amgen, 2002.
120. Neulasta® (pegfilgrastim) Product Information. Amgen, 2002.
121. Leukine® (sargramostim) Product Information. Berlex, 2002.
122. R. de Wit, J. Verweij, and M. Bontenbal Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support J Natl Cancer Inst 88 1996 1393 1398
123. M. Weintraub, M.A. Adde, and D.J. Venzon Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine J Clin Oncol 14 1996 935 940
124. Cisplatin Product Information. Mosby's Drug Consult. Available by subscription at: http://www.mosbysdrugconsult.com [accessed March 31, 2003].
125. Paraplatin® (carboplatin) Product Information. Bristol-Myers Squibb, 2001.
126. Vancocin® (vancomycin) Product Information. Eli Lilly, 2001.
127. R.J. Thomas Neurotoxicity of antibacterial therapy South Med J 87 1994 869 874
128. J. Shimada, S. Hori, and K. Kanemitsu A comparative study on the convulsant activity of carbapenems and beta-lactams Drugs Exp Clin Res 18 1992 377 381
129. P. Hantson, F. Leonard, J.M. Maloteaux, and P. Mahieu How epileptogenic are the recent antibiotics? Acta Clin Belg 54 1999 80 87
130. Zithromax® (azithromycin) Product Information. Pfizer, 2001.
131. QTdrugs.org. International registry for drug-induced arrhythmias. http://www.QTdrugs.org. [accessed August 18, 2003].
132. E.J. Johnson, A.P. MacGowan, and M.N. Potter Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy J Antimicrob Chemother 25 1990 837 842
133. Y.G. Yap, and A.J. Camm Potential cardiac toxicity of H1-antihistamines Clin Allergy Immunol 17 2002 389 419
134. Valtrex® (valacyclovir) Product Information. GlaxoSmithKline, 2001.
135. A. Parmeggiani, R. Riva, A. Posar, and P.G. Rossi Possible interaction between acyclovir and antiepileptic treatment Ther Drug Monitor 17 1995 312 315
136. Y. Maeda, T. Konishi, and K. Omoda Inhibition of theophylline metabolism by aciclovir Biol Pharm Bull 19 1996 1591 1595
137. C. Gridelli, F. Perrone, and C. Gallo Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomised trial J Natl Cancer Inst 95 2003 362 372
138. R. Yancik Epidemiology of cancer in the elderly: current status and projections for the future RAYS 22 Suppl 1997 3 9
139. A. Lindsey, P. Larson, M. Dodd, and M. Brecht Comorbidity, nutritional intake, social support, weight and functional status over time in older cancer patients receiving radiotherapy Cancer Nurs 17 1994 113 124
140. L.P. Fried, K. Bandeen-Roche, J.D. Kasper, and J.M. Guralnik Association of comorbidity with disability in older women: the women's health and aging study J Clin Epidemiol 52 1999 27 37
141. Foradil® (formoterol) Product Information. Novartis, 2001.
142. M. Cazzola, R. Testi, and M.G. Matera Clinical pharmacokinetics of salmeterol Clin Pharmacokinet 41 2002 19 30
143. I.C. Macdougall The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin Nephrol Dial Transplant 14 1999 1836 1841
144. C. Meune, I. Mahe, and J.J. Mourad Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review Eur J Clin Pharmacol 56 2000 609 620
145. C. Mignat, and T. Unger ACE inhibitors. Drug interactions of clinical significance Drug Saf 12 1995 334 347
146. A. Whelton Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics Am J Ther 7 2000 63 74
147. D.A. Flockhart, and J.E. Tanus-Santos Implications of cytochrome P450 interactions when prescribing medication for hypertension Arch Intern Med 162 2002 405 412
148. Oesterheld JR. P-glycoprotein drug interactions. http://www.mhc.com/PGP/ index.html [accessed April 23, 2003].
149. The Worldwide Physiologist: Cytochrome P450. http://www.anaesthetist.com/ physiol/basics/metabol/cyp/cyp.htm [accessed June 21, 2004].
150. H. Christensen, A. Asberg, A.B. Holmboe, and K.J. Berg Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers Eur J Clin Pharmacol 58 2002 515 520
151. D.G. Bailey, J.M. Arnold, J.R. Bend, L.T. Tran, and J.D. Spence Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation Br J Clin Pharmacol 40 1995 135 140
152. P.C. Ho, K. Ghose, D. Saville, and S. Wanwimolruk Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers Eur J Clin Pharmacol 56 2000 693 698
153. J. Vincent, S.I. Harris, G. Foulds, L.C. Dogolo, S. Willavize, and H.L. Friedman Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine Br J Clin Pharmacol 50 2000 455 463
154. S. Glaser, M. Steinbach, and C. Opitz Torsades de pointes caused by mibefradil Eur J Heart Fail 3 2001 627 630
155. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
156. V. Fischer, L. Johanson, and F. Heitz The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions Drug Metab Dispos 27 1999 410 416
157. J. Martin, and H. Krum Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 26 2003 13 21
158. C.M. Ballantyne, A. Corsini, and M.H. Davidson Risk for myopathy with statin therapy in high-risk patients Arch Intern Med 163 2003 553 564
159. Zocor® (simvastatin) Product Information. Merck Sharp & Dohme, 2004.
160. Mevacor® (lovastatin) Product Information. Merck & Co., Inc., 2002.
161. Lipitor® (atorvastatin) Product Information. Pfizer, 2004.
162. T. Bandrowsky, A.A. Vorono, T.J. Borris, and H.W. Marcantoni Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82 1996 610 612
163. P.S. Wells, A.M. Holbrook, N.R. Crowther, and J. Hirsh Interactions of warfarin with drugs and food Ann Intern Med 121 1994 676 683
164. G. Masci, M. Magagnoli, and P.A. Zucali Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 21 2003 736 739
165. L.H. Opie Adverse cardiovascular drug interactions Curr Probl Cardiol 25 2000 621 676
166. D. Kurnik, R. Loebstein, H. Rabinovitz, N. Austerweil, H. Halkin, and S. Almog Over-the-counter Vitamin K(1)-containing multivitamin supplements disrupt warfarin anticoagulation in Vitamin K(1)-depleted patients Thromb Haemost 92 2004 1018 1024
167. T. Khan, H. Wynne, and P. Wood Dietary Vitamin K influences intra-individual variability in anticoagulant response to warfarin Br J Haematol 124 2004 348 354
168. W.R. Bartle Grapefruit juice might still be factor in warfarin response Am J Health Syst Pharm 56 1999 676
169. D.M. Sullivan, M.A. Ford, and T.W. Boyden Grapefruit juice and the response to warfarin Am J Health Syst Pharm 55 1998 1581 1583
170. P.N. Maton, and M.E. Burton Antacids revisited. A review of their clinical pharmacology and recommended therapeutic use Drugs 57 1999 855 870
171. D.C. Sadowski Drug interactions with antacids. Mechanisms and clinical significance Drug Saf 11 1994 395 407
172. P.J. Neuvonen, and K.T. Kivisto Enhancement of drug absorption by antacids. An unrecognised drug interaction Clin Pharmacokinet 27 1994 120 128
173. R.A. Blum, D.T. D'Andrea, and B.M. Florentino Increased gastric pH and the bioavailability of fluconazole and ketoconazole Ann Intern Med 114 1991 755 757
174. D.R. Bickers Antifungal therapy: potential interactions with other classes of drugs J Am Acad Dermatol 31 1994 S87 S90
175. Anon. Systemic antifungal drugs. Med Lett Drugs Ther 1997;39:86-8.
176. Y. Kanda, M. Kami, and T. Matsuyama Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole Hematol Oncol 16 1998 33 37
177. J. Amchin, L. Ereshefsky, and W. Zarycranski Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe J Clin Pharmacol 41 2001 443 451
178. A. Erfurth, M. Loew, P. Dobmeier, and G. Wendler ECG changes after paroxetine. 3. Case reports Nervenarzt 69 1998 629 631 [article in German]
179. P. Varriale Fluoxetine (Prozac) as a cause of QT prolongation Arch Intern Med 151 2001 612
180. E. Spina, A. Avenoso, G.M. Campo, M.G. Scordo, A.P. Caputi, and E. Perucca Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects Br J Clin Pharmacol 43 1997 315 358
181. J. Schmider, D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, and R.I. Shader N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors J Pharmacol Exp Ther 275 1995 592 597
182. K. Venkatakrishnan, D.J. Greenblatt, L.L. von Moltke, J. Schmider, J.S. Harmatz, and R.I. Shader Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4 J Clin Pharmacol 38 1998 112 121
183. R.J. Baldessarini, and F.I. Tarazi Drugs and the treatment of psychiatric disorders. psychosis and mania J.G. Hardman LE. Limbird Goodman & Gilman's the pharmacological basis of therapeutics 10th ed 2002 McGraw-Hill New York City, NY 485 520
184. J.H. Brown, and P. Taylor Muscarinic receptor agonists and antagonists J.G. Hardman LE. Limbird Goodman & Gilman's the pharmacological basis of therapeutics 10th ed 2002 McGraw-Hill New York City, NY 155 172
185. H.B. Gutstein, and H. Akil Opioid analgesics J.G. Hardman LE. Limbird Goodman & Gilman's the pharmacological basis of therapeutics 10th ed 2002 McGraw-Hill New York City, NY 569 619
186. Demerol® (meperidine) Product Information. Sanofi-Synthelabo, 2000.
187. Robaxin® (methocarbamol) Product Information. Elkins-Sinn, 2001.
188. Flexeril® (cyclobenzaprine) Product Information. Merck, 1999.
189. Soma® (carisoprodol) Product Information. Wallace, 2001.
190. M. Ingelman-Sundberg, M. Oscarson, and R.A. McLellan Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment Trends Pharmacol Sci 20 1999 342 349
191. M. Kitada Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6 Int J Clin Pharmacol Res 23 2003 31 35
192. Xeloda® (capecitabine) Product Information. Roche, 2001.
193. Elspar® (asparaginase) Product Information. Merck, 2001.
194. Arava® (leflunomide) Product Information. Aventis, 2001.
195. E.A. Perez Paclitaxel and cardiotoxicity J Clin Oncol 16 1998 3481 3482 [editorial]
196. S. Jerian, and P. Keegan Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy (letter). Reply, Perez EA J Clin Oncol 17 1999 1647 1648
197. J.A. Sparano Cardiac toxicity of trastuzumab (herceptin): implications for the design of adjuvant trials Semin Oncol 28 1 Suppl 3 2001 20 27
198. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
199. Navelbine® (vinorelbine) Product Information. Glaxo Wellcome, 2001.
200. R. Kaiser, O. Sezer, and A. Papies Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes J Clin Oncol 20 2002 2805 2811
201. P.J. Cagnoni, S. Matthes, and T.C. Day Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics Bone Marrow Transplant 24 1999 1 4
202. C.J. Gilbert, W.P. Petron, and J. Vredenburgh Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer Cancer Chemother Pharmacol 42 1998 497 503
203. O.M. Koriech Fluoxetine treatment compromises the antiemetic efficacy of ondansetron in cancer patients Clin Oncol (R Coll Radiol) 7 1995 371 372
204. R. Arcioni, M. della Rocca, and S. Romano Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans Anesth Analg 94 2002 1553 1557
205. Axert® (almotriptan) Product Information. Pharmacia & Upjohn, 2001.
206. Nizoral® (ketoconazole) Product Information. Janssen, 2001.
207. R.F. Robinson, M.C. Nahata, and R.S. Olshefski Syncope associated with concurrent amitriptyline and fluconazole therapy Ann Pharmacother 34 2000 1406 1409
208. Klonopin® (clonazepam) Product Information. Roche, 2001.
209. J.D. Lazar, and K.D. Wilner Drug interactions with fluconazole Rev Infect Dis 12 Suppl 3 1990 S327 S333
210. K.M. Jalava, J. Partanen, and P.J. Neuvonen Itraconazole decreases renal clearance of digoxin Ther Drug Monit 19 1997 609 613
211. K. Yasuda, L.B. Lan, and D. Sanglard Interaction of cytochrome P450 3A inhibitors with P-glycoprotein J Pharmacol Exp Ther 303 2002 323 332
212. J.D. Chan Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports Pharmacotherapy 18 1998 1304 1307
213. Celexa® (citalopram) Product Information. Forest, 2002.
214. Prozac® (fluoxetine) Product Information. Dista, 2001.
215. Fluvoxamine Product Information. Mosby's Drug Consult. Available by subscription at: http://www.mosbysdrugconsult.com [accessed April 14, 2003].
216. Paxil® (paroxetine) Product Information. GlaxoSmithKline, 2002.
217. Zoloft® (sertraline) Product Information. Pfizer, 2002.